FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313479224> ?p ?o ?g. }

• W4313479224 endingPage "100461" @default.
• W4313479224 startingPage "100461" @default.
• W4313479224 abstract "We present the results of a phase 2a trial of first-line avelumab (anti-programmed death-ligand 1 antibody) plus cetuximab (anti-EGFR antibody) in patients with advanced squamous NSCLC.Patients with recurrent or metastatic squamous NSCLC received avelumab 800 mg (d 1 and 8), cetuximab 250 mg/m2 (d 1) and 500 mg/m2 (d 8), cisplatin 75 mg/m2 (d 1), and gemcitabine 1250 mg/m2 (d 1 and 8) for four 3-week cycles, followed by avelumab 800 mg and cetuximab 500 mg/m2 every 2 weeks. The primary end point was the best overall response; the secondary end points were progression-free survival, duration of response, overall survival, and safety. Efficacy analyses were reported from an updated data cutoff.A total of 43 patients were enrolled. The median follow-up was 6.6 months for the primary analyses and 9.2 months for the efficacy analyses. In the efficacy analyses, 15 patients had a confirmed partial response (objective response rate, 34.9% [95% confidence interval: 21.0%-50.9%]), and the median duration of response was 7.1 months (95% confidence interval: 4.2-12.5 mo). The median progression-free survival and overall survival were 6.1 months and 10.0 months, respectively. In the safety analyses (primary analysis), 38 patients (88.4%) had a treatment-related adverse event, of whom 24 (55.8%) had a grade 3 or higher treatment-related adverse event.The combination of avelumab + cetuximab and chemotherapy showed antitumor activity and tolerable safety; however, the ORR was not improved compared with those reported for current standards of care (NCT03717155)." @default.
• W4313479224 created "2023-01-06" @default.
• W4313479224 creator A5002019310 @default.
• W4313479224 creator A5002929462 @default.
• W4313479224 creator A5014364032 @default.
• W4313479224 creator A5015419018 @default.
• W4313479224 creator A5016207819 @default.
• W4313479224 creator A5020985643 @default.
• W4313479224 creator A5025063745 @default.
• W4313479224 creator A5030920745 @default.
• W4313479224 creator A5038777347 @default.
• W4313479224 creator A5042279259 @default.
• W4313479224 creator A5043177546 @default.
• W4313479224 creator A5043867460 @default.
• W4313479224 creator A5046536017 @default.
• W4313479224 creator A5046609856 @default.
• W4313479224 creator A5047634085 @default.
• W4313479224 creator A5054842148 @default.
• W4313479224 creator A5056452687 @default.
• W4313479224 creator A5066986444 @default.
• W4313479224 creator A5069675443 @default.
• W4313479224 creator A5087260997 @default.
• W4313479224 creator A5090324173 @default.
• W4313479224 date "2023-02-01" @default.
• W4313479224 modified "2023-10-07" @default.
• W4313479224 title "Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC" @default.
• W4313479224 cites W1988442083 @default.
• W4313479224 cites W2105834225 @default.
• W4313479224 cites W2113843552 @default.
• W4313479224 cites W2143699888 @default.
• W4313479224 cites W2155933329 @default.
• W4313479224 cites W2163351155 @default.
• W4313479224 cites W2167599107 @default.
• W4313479224 cites W2168340462 @default.
• W4313479224 cites W2198093519 @default.
• W4313479224 cites W2293531514 @default.
• W4313479224 cites W2560367415 @default.
• W4313479224 cites W2572174216 @default.
• W4313479224 cites W2599354912 @default.
• W4313479224 cites W2769988386 @default.
• W4313479224 cites W2775469584 @default.
• W4313479224 cites W2796582438 @default.
• W4313479224 cites W2805354595 @default.
• W4313479224 cites W2892640821 @default.
• W4313479224 cites W2893602866 @default.
• W4313479224 cites W2925446385 @default.
• W4313479224 cites W2946386783 @default.
• W4313479224 cites W2978539957 @default.
• W4313479224 cites W2981790403 @default.
• W4313479224 cites W3017322331 @default.
• W4313479224 cites W3084424287 @default.
• W4313479224 cites W3121907365 @default.
• W4313479224 cites W3129022890 @default.
• W4313479224 cites W3144903047 @default.
• W4313479224 cites W3165007730 @default.
• W4313479224 doi "https://doi.org/10.1016/j.jtocrr.2022.100461" @default.
• W4313479224 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36718142" @default.
• W4313479224 hasPublicationYear "2023" @default.
• W4313479224 type Work @default.
• W4313479224 citedByCount "0" @default.
• W4313479224 crossrefType "journal-article" @default.
• W4313479224 hasAuthorship W4313479224A5002019310 @default.
• W4313479224 hasAuthorship W4313479224A5002929462 @default.
• W4313479224 hasAuthorship W4313479224A5014364032 @default.
• W4313479224 hasAuthorship W4313479224A5015419018 @default.
• W4313479224 hasAuthorship W4313479224A5016207819 @default.
• W4313479224 hasAuthorship W4313479224A5020985643 @default.
• W4313479224 hasAuthorship W4313479224A5025063745 @default.
• W4313479224 hasAuthorship W4313479224A5030920745 @default.
• W4313479224 hasAuthorship W4313479224A5038777347 @default.
• W4313479224 hasAuthorship W4313479224A5042279259 @default.
• W4313479224 hasAuthorship W4313479224A5043177546 @default.
• W4313479224 hasAuthorship W4313479224A5043867460 @default.
• W4313479224 hasAuthorship W4313479224A5046536017 @default.
• W4313479224 hasAuthorship W4313479224A5046609856 @default.
• W4313479224 hasAuthorship W4313479224A5047634085 @default.
• W4313479224 hasAuthorship W4313479224A5054842148 @default.
• W4313479224 hasAuthorship W4313479224A5056452687 @default.
• W4313479224 hasAuthorship W4313479224A5066986444 @default.
• W4313479224 hasAuthorship W4313479224A5069675443 @default.
• W4313479224 hasAuthorship W4313479224A5087260997 @default.
• W4313479224 hasAuthorship W4313479224A5090324173 @default.
• W4313479224 hasBestOaLocation W43134792241 @default.
• W4313479224 hasConcept C121608353 @default.
• W4313479224 hasConcept C126322002 @default.
• W4313479224 hasConcept C143998085 @default.
• W4313479224 hasConcept C168563851 @default.
• W4313479224 hasConcept C197934379 @default.
• W4313479224 hasConcept C203092338 @default.
• W4313479224 hasConcept C2776694085 @default.
• W4313479224 hasConcept C2777381376 @default.
• W4313479224 hasConcept C2777701055 @default.
• W4313479224 hasConcept C2779984678 @default.
• W4313479224 hasConcept C2779998722 @default.
• W4313479224 hasConcept C2780057760 @default.
• W4313479224 hasConcept C31760486 @default.
• W4313479224 hasConcept C44249647 @default.
• W4313479224 hasConcept C526805850 @default.

• next